|
|
|
|
LEADER |
04397nam a2200997Ia 4500 |
001 |
10.1002-jcla.23815 |
008 |
220427s2021 CNT 000 0 und d |
020 |
|
|
|a 08878013 (ISSN)
|
245 |
1 |
0 |
|a Effect of miR-630 expression on esophageal cancer cell invasion and migration
|
260 |
|
0 |
|b John Wiley and Sons Inc
|c 2021
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.1002/jcla.23815
|
520 |
3 |
|
|a Background: Esophageal cancer (EC) is a common malignancy of the digestive tract, with high incidence. The objective of this study was to investigate the effect of miR-630 expression on esophageal cancer (EC) cell invasion and migration. Methods: The study group comprised 58 EC patients admitted to our hospital from April 2014 to 2016, and the control group comprised 60 healthy people visiting the hospital during the same period. miR-630 levels in the peripheral blood of the two groups were compared, and the diagnostic value of miR-630 for EC was analyzed. EC cell lines were used to evaluate the influence of miR-630 expression on EC cell invasion and migration. Results: miR-630 expression was low in EC (p < 0.050). A receiver operating characteristic curve analysis showed that miR-630 expression had a good diagnostic value for EC (p < 0.050) and was associated with disease course, pathological stage, differentiation degree, tumor metastasis, and patient prognosis and survival (p < 0.05). The ROC curve analysis showed that when cutoff value was 5.38, the diagnostic sensitivity and specificity of miR-630 for EC were 73.33% and 76.67%, respectively; area under the ROC curve was 0.778 (95%CI 0.695–0.861). Transfection of miR-630 into EC cells indicated that miR-630 overexpression can reduce EC cell invasion and migration (p < 0.05). miR-630 expression is low in EC and has good diagnostic value for EC. Conclusion: miR-630 overexpression can reduce EC cell invasion and migration, showing a possible key role of miR-630 in EC diagnosis and treatment in the future. © 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC
|
650 |
0 |
4 |
|a adult
|
650 |
0 |
4 |
|a apoptosis
|
650 |
0 |
4 |
|a Apoptosis
|
650 |
0 |
4 |
|a Article
|
650 |
0 |
4 |
|a Biomarkers, Tumor
|
650 |
0 |
4 |
|a blood level
|
650 |
0 |
4 |
|a cancer prognosis
|
650 |
0 |
4 |
|a cancer staging
|
650 |
0 |
4 |
|a cancer survival
|
650 |
0 |
4 |
|a case control study
|
650 |
0 |
4 |
|a Case-Control Studies
|
650 |
0 |
4 |
|a cell invasion
|
650 |
0 |
4 |
|a cell migration
|
650 |
0 |
4 |
|a cell motion
|
650 |
0 |
4 |
|a Cell Movement
|
650 |
0 |
4 |
|a cell proliferation
|
650 |
0 |
4 |
|a Cell Proliferation
|
650 |
0 |
4 |
|a comparative study
|
650 |
0 |
4 |
|a controlled study
|
650 |
0 |
4 |
|a diagnostic test accuracy study
|
650 |
0 |
4 |
|a diagnostic value
|
650 |
0 |
4 |
|a diagnostic value
|
650 |
0 |
4 |
|a disease course
|
650 |
0 |
4 |
|a esophageal cancer
|
650 |
0 |
4 |
|a esophageal cancer cell line
|
650 |
0 |
4 |
|a Esophageal Neoplasms
|
650 |
0 |
4 |
|a esophagus cancer
|
650 |
0 |
4 |
|a esophagus tumor
|
650 |
0 |
4 |
|a female
|
650 |
0 |
4 |
|a Female
|
650 |
0 |
4 |
|a gene expression
|
650 |
0 |
4 |
|a gene expression regulation
|
650 |
0 |
4 |
|a Gene Expression Regulation, Neoplastic
|
650 |
0 |
4 |
|a gene overexpression
|
650 |
0 |
4 |
|a genetics
|
650 |
0 |
4 |
|a hospital admission
|
650 |
0 |
4 |
|a human
|
650 |
0 |
4 |
|a human cell
|
650 |
0 |
4 |
|a Humans
|
650 |
0 |
4 |
|a invasion
|
650 |
0 |
4 |
|a major clinical study
|
650 |
0 |
4 |
|a male
|
650 |
0 |
4 |
|a Male
|
650 |
0 |
4 |
|a metabolism
|
650 |
0 |
4 |
|a metastasis
|
650 |
0 |
4 |
|a microRNA
|
650 |
0 |
4 |
|a microRNA
|
650 |
0 |
4 |
|a microRNA 630
|
650 |
0 |
4 |
|a MicroRNAs
|
650 |
0 |
4 |
|a middle aged
|
650 |
0 |
4 |
|a Middle Aged
|
650 |
0 |
4 |
|a migration
|
650 |
0 |
4 |
|a miR-630
|
650 |
0 |
4 |
|a MIRN630 microRNA, human
|
650 |
0 |
4 |
|a Neoplasm Invasiveness
|
650 |
0 |
4 |
|a pathology
|
650 |
0 |
4 |
|a prognosis
|
650 |
0 |
4 |
|a Prognosis
|
650 |
0 |
4 |
|a sensitivity and specificity
|
650 |
0 |
4 |
|a survival rate
|
650 |
0 |
4 |
|a Survival Rate
|
650 |
0 |
4 |
|a tumor cell culture
|
650 |
0 |
4 |
|a Tumor Cells, Cultured
|
650 |
0 |
4 |
|a tumor invasion
|
650 |
0 |
4 |
|a tumor marker
|
650 |
0 |
4 |
|a unclassified drug
|
700 |
1 |
|
|a Liao, K.
|e author
|
700 |
1 |
|
|a Liu, X.
|e author
|
700 |
1 |
|
|a Qiu, Y.
|e author
|
700 |
1 |
|
|a Tan, W.
|e author
|
700 |
1 |
|
|a Wu, W.
|e author
|
700 |
1 |
|
|a Yang, K.
|e author
|
700 |
1 |
|
|a Zhang, S.
|e author
|
773 |
|
|
|t Journal of Clinical Laboratory Analysis
|